Advertisement

Topics

AbbVie, Voyager Launch $1.5B+ Gene Therapy Collaboration Aimed at Parkinson’s, Other Synucleinopathies

10:20 EST 22 Feb 2019 | Genetic Engineering News

AbbVie and Voyager Therapeutics said today they will launch a potentially $1.5 billion-plus gene therapy collaboration—the companies’ second billion-dollar-plus alliance in as many years, with the new partnership focused on treating Parkinson’s disease and other diseases characterized by abnormal accumulation of misfolded alpha-synuclein protein. The companies said they plan to develop “one or more” treatments […]

The post AbbVie, Voyager Launch $1.5B+ Gene Therapy Collaboration Aimed at Parkinson’s, Other Synucleinopathies appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: AbbVie, Voyager Launch $1.5B+ Gene Therapy Collaboration Aimed at Parkinson’s, Other Synucleinopathies

NEXT ARTICLE

More From BioPortfolio on "AbbVie, Voyager Launch $1.5B+ Gene Therapy Collaboration Aimed at Parkinson’s, Other Synucleinopathies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...